The Covid windfall exhausted, Big Pharma is accelerating on other treatments. Large pharmaceutical laboratories are increasing their investments in innovative treatments.
Pfizer's turnover fell by 42% in a single year. Demand for its Comirnaty vaccine turned out to be lower than expected, 6 billion euros lower than in 2022. The same was true for its antiviral treatment against Covid, Paxlovid. The Swiss laboratory's sales fell by 7% last year... This article is reserved for subscribers. You have 84% left to discover. Flash sale -70% on digital subscription I ENJOY IT Already subscribed? Log in.